Endo Inc Stock Price, News & Analysis

Mallinckrodt and Endo announced their planned leadership structure following their upcoming merger, scheduled for completion in H2 2025. The merged entity will create two distinct companies: a branded specialty pharmaceuticals company and Par Health, a spin-off focusing on generics and sterile injectables (GxSI). Siggi Olafsson, current Mallinckrodt CEO, will lead the merged company. The leadership team combines executives from both companies, including Tracy Basso (CHRO), Mark Bradley (Chief Integration Officer), Lisa French (CCO), and others. Stephen Welch, currently Head of Specialty Generics at Mallinckrodt, will become CEO of Par Health post-spin-off. The company is actively recruiting for key positions including CFO, Business Development & Strategy, and R&D leadership. The merger remains subject to shareholder approval and customary closing conditions.

Endo (OTCQX: NDOI) has launched a comprehensive Men's Health Month initiative for June 2025, focusing on raising awareness and education about men's health issues. The campaign targets underdiagnosed and stigmatized conditions including Peyronie's disease, erectile dysfunction, and testosterone deficiency. Key activities include digital outreach through social media, educational materials distribution in healthcare settings, email campaigns with clinical insights, and website content development. The company will participate in Wear Blue Day on June 13 to support men's health awareness. Justin Mattice, SVP & GM of Branded Specialty, emphasized the importance of empowering men to take an active role in their health management through proper information and awareness.

Endo (OTCQX: NDOI) has announced the launch of ADRENALIN® 8 mg/250 mL premixed bag, expanding its ready-to-use epinephrine product line. The product will begin shipping on May 19, 2025. ADRENALIN® holds the distinction of being the first FDA-approved and only commercially available manufacturer-prepared epinephrine premixed IV bag. The product offers key benefits including no compounding requirements, single-port IV tubing, and 24-month shelf life at room temperature. The company currently offers 4 mg/250 mL premixed bags and plans to launch 5 mg/250 mL and 10 mg/250 mL concentrations. ADRENALIN® is indicated for increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.

The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.

Endo reported Q1 2025 financial results with total revenues of $393 million, down 6% from Q1 2024. XIAFLEX® revenues grew 7% to $121 million, driving Branded Pharmaceuticals segment growth. The company reported a net loss of $129 million, improved from $154 million loss in Q1 2024. Adjusted EBITDA decreased 32% to $99 million. Endo reaffirmed its 2025 guidance with expected revenues of $1,775-$1,860 million and adjusted EBITDA of $620-$650 million. Two major transactions were announced: a merger with Mallinckrodt where Endo shareholders will receive $80 million and own 49.9% of the combined company (expected to close in H2 2025), and the planned divestiture of its International Pharmaceuticals business (expected to close mid-2025).

Endo (OTCQX: NDOI) has announced the launch of a Spatial Computing Injection Simulator for Peyronie's disease, set to debut at the American Urological Association Annual Meeting (April 26-29, 2025). The innovative simulator combines physical penile models with digital content through an Apple Vision Pro app, creating an immersive learning environment for urology specialists.

The 20-minute training experience helps healthcare providers refine their injection technique for XIAFLEX®, the only FDA-approved nonsurgical treatment for Peyronie's disease. The simulator offers hands-on practice for product reconstitution, injection angles, procedure demonstrations, and post-injection process information.

This marks Endo's second venture into spatial computing for medical training, following a previous development for hand specialists treating Dupuytren's contracture. The company collaborated with technology agency Lucid Dream to develop the Apple Vision Pro application.

Endo (OTCQX: NDOI) has scheduled the release of its first quarter 2025 financial results for May 7, 2025, before the market opens. The company will hold a conference call at 8:30 a.m. ET on the same day.

Investors can access the audio webcast through the company's Investor Relations website at investor.endo.com under Events & Presentations. For those joining via phone, the dial-in numbers are 800-836-8184 (U.S. and Canada toll-free) and 646-357-8785 (international). Participants should connect 10 minutes before the scheduled start time. A webcast replay will be made available after the event.

Endo (OTCQX: NDOI) has launched the Spatial Computing Injection Simulator, becoming the first pharmaceutical company to introduce an external spatial computing program. The simulator, utilizing Apple Vision Pro technology, creates an immersive learning environment for hand specialists administering XIAFLEX®, the only FDA-approved nonsurgical treatment for Dupuytren's contracture.

The 20-minute experience combines physical hand models with digital content, allowing healthcare providers to practice reconstitution, injection angles, and post-injection procedures. The technology has already garnered significant interest at medical conferences, with over 600 hand specialists testing it at the American Society for Surgery of the Hand (ASSH) and American Association for Hand Surgery (AAHS) annual meetings.

The simulator is now available through Endo's orthopedics sales team, developed in partnership with technology agency Lucid Dream for the Apple Vision Pro platform.

Endo (OTCQX: NDOI) announced the presentation of data regarding XIAFLEX® (collagenase clostridium histolyticum) for treating recurrent Dupuytren contracture after surgical correction at the IFSSH and IFSHT Triennial Congress (March 24-28, 2025).

Dupuytren contracture, affecting an estimated 17 million Americans, is a progressive hand condition where collagen cords form under the palm's skin, causing fingers to pull inward. The Phase 4 retrospective study data explores XIAFLEX® as an alternative to repeat surgery for patients experiencing recurrent deformity after initial successful surgery.

Dr. Clayton A. Peimer, Adjunct Clinical Professor of Orthopedics at Brown University's Warren Alpert Medical School and lead study author, emphasized the importance of these findings for healthcare providers managing recurrent cases of Dupuytren contracture.